Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Wed Apr 02 08:00:58 GMT 2025
by
admin
on
Wed Apr 02 08:00:58 GMT 2025
|
| Protein Type | MONOCLONAL ANTIBODY |
| Protein Sub Type | IGG1 |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
73B0K5S26A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
L04AA26
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
||
|
NDF-RT |
N0000182637
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
||
|
FDA ORPHAN DRUG |
921522
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
||
|
NCI_THESAURUS |
C20401
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
||
|
WHO-VATC |
QL04AA26
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
BENLYSTA (AUTHORIZED LUPUS ERYTHEMSTOSUS, SYSTEMIC)
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4949
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
OO-56
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
BELIMUMAB
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
6887
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
73B0K5S26A
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
73B0K5S26A
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
N0000182156
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | Decreased B Lymphocyte Activation [PE] | ||
|
CHEMBL1789843
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
356547-88-1
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
100000090056
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
1092437
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | RxNorm | ||
|
N0000182636
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | B Lymphocyte Stimulator-directed Antibody Interactions [MoA] | ||
|
SUB25607
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
m2294
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
8381
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
DB08879
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
C91385
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY | |||
|
Belimumab
Created by
admin on Wed Apr 02 08:00:58 GMT 2025 , Edited by admin on Wed Apr 02 08:00:58 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_22 | 1_96 |
| 2_22 | 2_96 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO_ACID_SUBSTITUTION | [1_1] [2_1] | Q | PIDOLIC ACID | SZB83O1W42 |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:SEQUENCE | CHEMICAL |
|
||||